Compare KKR & Co Inc (KKR) vs Eli Lilly And Co (LLY) Price & Performance

KKR trades at $89.56, down 0.12% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. Recent earnings show a mixed track record, with Q2 2026 beating estimates but Q4 2025 missing. The company maintains strong analyst support with a consensus price target of $123.30 and 24 buy ratings. Recent news highlights active deal-making, including a joint venture with Thomson Reuters and investments in AI infrastructure, signaling ongoing strategic expansion.

The outlook for KKR is positive based on robust analyst sentiment and strategic investments, but risks include volatile cash flows and high debt levels. Investors may find opportunity in the significant upside to the price target, though macroeconomic sensitivity and execution risks warrant caution.

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.

LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.